An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Eli Lilly’s boss, Dave Ricks, told an Indian business TV interviewer that the recent arrival of much cheaper branded generic semaglutide in India hasn’t derailed Lilly’s plans. He was responding to news that some companies in India are selling semaglutide — the same active drug as in popular weight-loss and diabetes medicines — at prices far below what Lilly charges for its drug Mounjaro. Ricks also suggested that ultra-low introductory prices can be misleading, implying they don’t reflect long-term market reality. Semaglutide is a lab-made version of a hormone your gut releases after eating. That hormone helps signal to your brain that you’re full and slows how fast your stomach empties. Big-name drugs like Ozempic and Wegovy use semaglutide (or very similar molecules) to treat type 2 diabetes and to help with weight loss. Mounjaro, the drug Lilly sells, is a different but related medicine aimed at metabolism and diabetes; the conversation here compares prices and market moves between those kinds of drugs. What the CEO said is about business strategy and pricing, not a new scientific finding. He’s saying that even though cheaper branded generics of semaglutide have entered the Indian market at very low prices, Lilly doesn’t see that as changing its overall trajectory — meaning its product plans, sales expectations, and investments. He also called very low initial prices “a bit of a fake signal,” suggesting they might be temporary or not sustainable. This is a company executive’s view; it reflects corporate positioning and market expectations rather than independent proof that prices will or won’t stay low. Why this matters to regular people: pricing and competition affect how easy it is to get these medicines and what they cost. If cheaper branded generics stick around, more patients might afford semaglutide-based treatments in places like India. Investors, doctors, and patients watch comments from big pharma leaders because those remarks can hint at future drug availability, price trends, and which companies will push harder on marketing or new products. For people concerned about access, the big-picture outcome—whether lower prices survive—will make a real difference. Caveats and risks: Ricks’s comments are corporate perspective, not independent analysis. He may be signaling confidence to investors or downplaying threats to pricing power. The snippet doesn’t say whether those low-priced products are widely used, how they compare in quality, or how regulators view them. Also, pricing and availability can vary a lot by country and over time. This conversation doesn’t change drug safety or clinical effectiveness — it’s about market dynamics. Bottom line: it’s mainly a business story about prices and competition, not a new medical finding.
Source: LinkedIn